Synaffix adds to the flurry of ADC dealmaking as it partners with Boehringer and Mitsubishi Tanabe with deals announced on ...

Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to ...

This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other ...

JERSEY CITY, N.J., Dec. 4, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of two abstracts on investigational ND0612 in Parkinson's disease (PD ...

AMSTERDAM, Jan. 9, 2025 /PRNewswire/ -- Synaffix B.V. ("Synaffix"), a Lonza company (SWX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody ...

March 2024: Moleac Pte Ltd announced a study of Phase 4 clinical trials for NeuroAiD. SATURN investigates the promising role ...

Mitsubishi Tanabe Pharma Corp. has identified serine/threonine-protein salt-inducible kinases (SIK) inhibitors reported to be useful for the treatment of psoriatic arthritis, lupus nephritis, ...

today announced that it has licensed its ADC technology to Mitsubishi Tanabe Pharma Corporation ("MTPC"), the pharma arm of Mitsubishi Chemical Group ("MCG"). Synaffix is responsible for the ...

Find out more at Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Group (MCG), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ...

License agreement centered around development of a single ADC programUsage of Synaffix GlycoConnect®, HydraSpace® and toxSYN® ADC technologies to enhance efficacy, tolerability and target engagementAM ...